TrialBlood cancer journal2019

Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma.

Heinz Ludwig et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.